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ABSTRACT
Objective To determine whether once-daily
esomeprazole 40 mg or 20 mg compared with placebo
reduces the incidence of peptic ulcers over 26 weeks of
treatment in patients taking low-dose acetylsalicylic acid
(ASA) and who are at risk for ulcer development.
Design Multinational, randomised, blinded, parallel-
group, placebo-controlled trial.
Setting Cardiology, primary care and gastroenterology
centres (n¼240).
Patients Helicobacter pylori-negative patients taking
daily low-dose ASA (75e325 mg), who fulﬁlled one or
more of the following criteria: age $18 years with
history of uncomplicated peptic ulcer; age $60 years
with either stable coronary artery disease, upper
gastrointestinal symptoms and ﬁve or more gastric/
duodenal erosions, or low-dose ASA treatment initiated
within 1 month of randomisation; or age $65 years. All
patients were ulcer-free at study entry.
Interventions Once-daily, blinded treatment with
esomeprazole 40 mg, 20 mg or placebo for 26 weeks.
Main outcome measures The primary end point was
the occurrence of endoscopy-conﬁrmed peptic ulcer over
26 weeks.
Results A total of 2426 patients (52% men; mean age
68 years) were randomised. After 26 weeks,
esomeprazole 40 mg and 20 mg signiﬁcantly reduced the
cumulativeproportionofpatientsdevelopingpepticulcers;
1.5% of esomeprazole 40 mg and 1.1% of esomeprazole
20 mg recipients, compared with 7.4% of placebo
recipients, developed peptic ulcers (both p<0.0001 vs
placebo). Esomeprazole was generally well tolerated.
Conclusions Acid-suppressive treatment with
once-daily esomeprazole 40 mg or 20 mg reduces the
occurrence of peptic ulcers in patients at risk for ulcer
development who are taking low-dose ASA.
Clinical trial registration number ClinicalTrials.gov
identiﬁer: NCT00441727.
INTRODUCTION
For patients at increased cardiovascular risk,
continuous low-dose acetylsalicylic acid (ASA,
aspirin; 75e325 mg/day) reduces the risk of a range
of cardiovascular events.
1 2 Low-dose ASA is
a mainstay of protective treatment for secondary
prevention of cardiovascular events, and is recom-
mended for primary prevention in patients at high
cardiovascular risk.
34In the most recent meta-
analysis conducted by the Antithrombotic Trialists’
Collaboration, low-dose ASA was associated with
a signiﬁcantly lower risk of serious vascular events
(eg, myocardial infarction, stroke or vascular death)
in secondary cardiovascular prevention trials.
1 In
primary prevention trials, a signiﬁcant reduction in
serious vascular events was due mainly to a reduc-
tion in non-fatal myocardial infarction, whereas
stroke and vascular mortality were not signiﬁcantly
reduced. The beneﬁt in primary prevention trials
was offset by a signiﬁcant increase in the risk of
major gastrointestinal and extracranial bleeding.
Even at low doses, ASA is associated with
gastrointestinal adverse effects, particularly in
patients who are at increased gastrointestinal risk
such as older patients and those with a previous
history of ulcer disease.
5 Low-dose ASA-associated
adverse gastrointestinal effects range from trou-
blesome upper gastrointestinal problems such as
dyspeptic symptoms and heartburn
67to serious
peptic ulcer complications, including gastrointes-
tinal bleeding
68and perforated ulcers.
9 Peptic ulcer
complications have been reported to occur more
than twice as frequently among low-dose ASA
users than controls,
10 11 even among patients
taking low-dose ASA for >3 months.
12 The risk of
gastrointestinal bleeding remains elevated with
longer duration of ASAtreatment
13; indeed, the risk
of gastrointestinal bleeding after 1 year of ASA use
is more than double relative to non-users.
11
Furthermore, the incidence of upper gastrointes-
tinal bleeding has increased in parallel with the
widespread use of low-dose ASA.
14 Use of enteric-
coated or buffered formulations of low-dose ASA
may not mitigate the risk of gastrointestinal
complications.
10 Gastrointestinal bleeding can
occur without preceding symptoms,
15 and may
lead to discontinuation of low-dose ASA treat-
ment.
16 Adverse upper gastrointestinal symptoms
with low-dose ASA use may lead to poor adherence
to, or discontinuation of, low-dose ASA treat-
ment
17; this is worrying as discontinuation is
associated with a markedly increased risk of serious
adverse cardiovascular events that can occur within
a few weeks.
18 Therefore, continuing to treat
patients at cardiovascular risk with long-term low-
dose ASA is key in the management of cardiovas-
cular disease.
19 For these reasons, concomitant
gastroprotection with a proton pump inhibitor
(PPI) is recommended for cardiovascular patients
who require continuous low-dose ASA and are at an
increased gastrointestinal risk.
20
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Clinical trialsThe OBERON trial explored primarily the efﬁcacy of esome-
prazole, at once-daily doses of 40 mg and 20 mg, compared with
placebo, in the prevention of peptic ulcers associated with
continuous use of low-dose ASA in patients who were at an
increased risk of developing peptic ulcers.
PATIENTS AND METHODS
OBERON was a randomised, blinded, parallel-group, placebo-
controlled trial (ClinicalTrials.gov identiﬁer: NCT00441727;
AstraZeneca study code: D961FC00003), conducted at 240
cardiology, primary care and gastroenterology centres in 20
countries (Argentina, Australia, Bulgaria, Canada, Czech
Republic, Finland, Germany, Indonesia, Mexico, Norway,
Philippines, Poland, Portugal, Romania, Russia, Slovakia, South
Africa, South Korea, Thailand and USA) in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines.
Patients, healthcare providers, data collectors and outcome
adjudicators were blinded to treatment allocation. The study
protocol was approved by the relevant local institutional review
boards or independent ethics committees of each study centre,
according to local regulations. All patients provided written,
informed consent before enrolment in the trial. The ﬁrst patient
was randomised to the study on 22 February 2007 and the last
patient completed the study on 28 August 2008.
Patients
Patients whose doctor prescribed or recommended daily use
($5 days/week) of low-dose ASA (75e325 mg/day) and who
were Helicobacter pylori negative at screening were eligible to
participate if they fulﬁlled one or more of the following inclusion
criteria: aged $18 years with documented history of uncompli-
cated peptic ulcer; aged $60 years with one or more risk factor
(stable coronary artery disease, or complaints of upper gastro-
intestinal symptoms that, as judged by the investigator, required
an endoscopy resulting in a ﬁnding of ﬁve or more gastric and/or
duodenal erosions at baseline endoscopy, or low-dose ASA-naïve
(ie, treatment was initiated within 1 month of randomisation));
or aged $65 years. Patients at very high cardiovascular and/or
gastrointestinal risk were excluded from the study for ethical
reasons. Cardiovascular exclusion criteria were unstable hyper-
tension; recent (within 3 months) experience of acute coronary
syndromes, percutaneous coronary intervention, coronary artery
bypass grafting, clinically relevant valvular disease, serious
cardiac failure (New York Heart Association class IIeIV or ejec-
tion fraction <40%) and stroke. Gastrointestinal exclusion
criteria were Los Angeles grade CeD erosive (reﬂux) oesophagitis
at baseline; patient-reported severe oesophagitis within 1 year;
peptic ulcer at baseline; history of peptic ulcer complications
(eg, clinically signiﬁcant bleeding and/or perforation) and
previous gastric or duodenal surgery (patients who had under-
gone laparoscopic fundoplication were eligible). Other exclusion
criteria were unstable diabetes mellitus: continuous treatment
with a non-steroidal anti-inﬂammatory drug within 2 months
of randomisation; ongoing anticoagulant treatment (anti-
platelets such as clopidogrel were permitted); use of drugs
that interact with esomeprazole (phenytoin, ketoconazole,
itraconazole, voriconazole, cisapride, atazanavir, ritonavir); use
of a PPI or prostaglandin analogue within 14 days of baseline
endoscopy, or between baseline endoscopy and randomisation;
daily use of histamine 2-receptor antagonists within 14 days of
baseline endoscopy; and need for continuous treatment with
prostaglandin analogues or sucralfate.
H pylori tests were performed according to local routine
practice and patients who were H pylori positive had to have
completed eradication treatment $4 weeks before random-
isation. Baseline H pylori status was subsequently conﬁrmed by
a[
13C]urea breath test and analysed by a central laboratory
(Quintiles, Research Triangle Park, North Carolina, USA);
conﬁrmation test results were blinded to the investigator during
the course of the study.
Treatment and design
After endoscopy and in addition to the low-dose ASA regimen
prescribed by their doctor, eligible patients were randomised
sequentially by numbered, opaque coded envelopes (in blocks of
six) to 26 weeks’ oral treatment with esomeprazole capsules at
once-daily doses of 40 mg or 20 mg, or placebo (in a ratio of
1:1:1). The randomisation codes were assigned from a computer-
generated list held by the study sponsor (AstraZeneca R&D,
Mölndal, Sweden); code envelopes were used as an emergency
unblinding tool. Esomeprazole and placebo capsules were
supplied by the study sponsor and were identical in appearance
and packaged in identical containers. Patients were instructed to
take the study drug in the morning before breakfast with a glass
of water. A rescue drug (antacids with acid-binding capacity of
<16 mmol HCl/tablet) was provided for use as needed (#6
tablets/day). Patients returned used study drug containers,
rescue drug containers and all unused drugs to the study
personnel at each study visit for assessment of drug adherence
and rescue-drug use.
Outcomes
The primary end point was endoscopy-conﬁrmed peptic (gastric
or duodenal) ulcer during the 26-week treatment period. An
ulcer was deﬁned as a mucosal break measuring $3 mm over its
largest diameter (size conﬁrmed with endoscopy forceps) with
a base (smooth or regular punched-out defect in the mucosa)
and margin (discrete, sharply demarcated and usually raised in
relation to the base) and the absence of any malignancy features.
Endoscopy for investigation of peptic ulcers was performed at
baseline, and at weeks 8 and 26 or upon withdrawal.
Secondary end points included the occurrence of a gastric
ulcer and, separately, a duodenal ulcer, over 26 weeks of treat-
ment, and safety and tolerability of treatments. Safety and
tolerability during 26 weeks of treatment with esomeprazole or
placebo were evaluated by assessments of adverse events and
vital signs (including blood pressure and pulse rate), and by
monitoring standard clinical laboratory tests and physical
examinations. Spontaneously reported adverse events and those
reported in response to a standardised question were recorded at
all scheduled (weeks 8, 16 and 26) and unscheduled visits.
Statistical analyses
The primary analysis for the efﬁcacy variables was based on the
intention-to-treat (ITT) population, deﬁned as all patients
who were randomised. A supportive analysis for the primary
end point was also conducted for the per-protocol population,
which consisted of those patients in the ITT population with no
major protocol violations, such as deviation from the inclusion/
exclusion criteria, or insufﬁcient intake of the study drug.
The cumulative incidence of peptic, duodenal and gastric
ulcer(s) was estimated from KaplaneMeier life tables, and treat-
ment groups were compared with placebo using the log-rank test
stratiﬁed by ASA dose (75e100 mg and 101e325 mg). Patients
who did not complete the 26 weeks for other reasons than the
development of an ulcer were censored at the time of study
discontinuation.Peptic,gastricandduodenalulcersweretestedin
a hierarchical closed-test procedure, which was performed in
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Clinical trialsparallel for the two esomeprazole doses with adjustment for
multiplicity, using the Hochberg procedure, in each step. The
effect of esomeprazole treatment on peptic ulcer incidence,
stratiﬁed by ASA dose (75e100 mg and 101e325 mg), was
analysed post hoc using Fisher’s exact test. Analyses were
conducted using SAS software (version 8.2; SAS Institute Inc).
Sample-size calculation
Based on data from a previous trial
21 and the assumption that
this study population had a higher gastrointestinal risk, we
assumed an event rate for peptic ulcers in the placebo group and
esomeprazole recipients of 8.0% and 3.2%, respectively, corre-
sponding to a relative risk reduction (RRR) of 60%. We also
assumed that 70% of the ulcers would be gastric. A sample size
of 2400 patients (800 per treatment arm) was selected to provide
90% power for the primary end point (two-sided a¼0.05) at the
2.5% signiﬁcance level, assuming a drop-out rate of 15%.
RESULTS
Patients
A total of 2426 patients were randomised; all randomised
patients were included in the ITT population as follows:
esomeprazole 40 mg (n¼817), esomeprazole 20 mg (n¼804) or
placebo (n¼805) (ﬁgure 1). Among the randomised patients, few
(3.4%) received concomitant clopidogrel treatment at any time
during the study. Patient baseline characteristics were similar
between treatment groups (table 1).
The per-protocol population included 1534 patients (esome-
prazole 40 mg, 525 patients; esomeprazole 20 mg, 526 patients;
placebo, 483 patients). The main reason for exclusion from the
per-protocol population in all treatment groups was a positive
H pylori test at study conclusion or missing H pylori status. The
safety analysis included all patients who received one or more
dose of investigational treatment and provided any follow-up
data.
The majority (94%) of patients were adherent (took $75% of
doses) to esomeprazole. Patients used their own prescribed or
recommended low-dose ASA tablets on $5 days/week, which
were not counted.
Incidence of ulcers
Among the ITT population, the life table estimated cumulative
peptic ulcer incidence over the 26-week treatment period was
1.5% (95% CI 0.6% to 2.4%) in esomeprazole 40 mg recipients,
1.1% (95% CI 0.3% to 1.9%) in esomeprazole 20 mg recipients
and 7.4% (95% CI 5.5% to 9.3%) among placebo recipients (both
p<0.0001 vs placebo), resulting in an RRR versus placebo of 80%
in esomeprazole 40 mg recipients and 85% in esomeprazole
20 mg recipients (ﬁgure 2), and an absolute risk reduction of
5.9% and 6.3%, respectively. The result of the corresponding per-
protocol analysis, from which H pylori-positive patients were
excluded, was consistent with the result of the ITTanalysis. The
observed incidence of peptic ulcer(s) in the ITT population was
11 esomeprazole 40 mg recipients (1.3%), 8 esomeprazole 20 mg
recipients (1.0%) and 53 placebo recipients (6.6%). The peptic
ulcer incidence at 26 weeks in H pylori-negative (n ¼1785) versus
H pylori-positive (n¼479) patients in the placebo arm was
similar (6.8% and 5.8%, respectively). Esomeprazole 40 mg and
20 mg reduced the occurrence of peptic ulcer to <2%, relative to
placebo, irrespective of H pylori status.
Overall, gastric ulcers were more prevalent than duodenal
ulcers in all treatment groups. Two placebo recipients with
negative and missing H pylori status, respectively, developed
both duodenal and gastric ulcers. When ulcer incidence
according to location was evaluated (data not shown), esome-
prazole 40 mg resulted in RRRs of 74% and 90% for gastric and
duodenal ulcers, respectively, versus placebo, while the respec-
tive RRRs for esomeprazole 20 mg were 83% and 90% (all
p<0.0001 vs placebo; ITT population).
In total, 79% of patients used daily low-dose ASA within the
range of 75e100 mg. A post hoc analysis determined that
esomeprazole 40 mg and 20 mg signiﬁcantly reduced peptic ulcer
incidence versus placebo in patients who used ASA within this
range (1.6% and 0.6% vs 6.1% of patients, respectively;
Figure 1 Patient ﬂow through the
study. All randomised patients are
included in the intention-to-treat (ITT)
analyses, including those patients who
did not complete 26 weeks of
treatment. Lack of response was
deﬁned as development of gastric
and/or duodenal ulcer and/or upper
gastrointestinal symptoms requiring
active intervention; the study-speciﬁc
discontinuation criterion was deﬁned as
low-dose acetylsalicylic acid (ASA)
treatment permanently stopped; severe
non-compliance was deﬁned as all
other forms of non-compliance except
stopping low-dose ASA treatment;
safety reasons were deﬁned as those to
protect study subjects from potential
safety risksdfor example, new data
causing study termination or
subpopulation of subjects to be
discontinued. All discontinuations were
judged by the study investigators.
aTwo
patients had positive Helicobacter pylori
status and ulcer at baseline endoscopy;
bsix patients had Los Angeles(LA)
grade C or D erosive (reﬂux) oesophagitis and ulcer at baseline endoscopy.
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Clinical trialsp<0.0001). Similar ﬁndings were noted in patients who used
ASA within the range of 101e325 mg (0.6% and 2.3% vs 8.7% of
patients, respectively; p<0.02).
Safety and tolerability
Gastrointestinal complications
Few gastrointestinal complications were reported. By week 26,
upper gastrointestinal complications were reported in two
esomeprazole 20 mg recipients (haematemesis (n¼1) and distal
duodenal perforation thought to be associated with a known
juxtapapillary diverticulum (n¼1)), three placebo recipients
(melaena (n¼2) and decreased haemoglobin level (n¼1)), and no
esomeprazole 40 mg recipients.
Other adverse events
Overall, esomeprazole 40 mg and 20 mg were well tolerated,
displaying similar tolerability proﬁles to placebo over 26 weeks
of treatment. Adverse events were reported with a similar
frequency in the three treatment groups (table 2). The most
commonly reported adverse events were diarrhoea, headache and
bronchitis. Overall, nine deaths occurred during the study (four
esomeprazole 40 mg, four esomeprazole 20 mg and one placebo
recipient); however, none of these were considered by the study
investigator at the centre to be causally related to the study
drug. The causes of death (as reported by study investigators)
were myocardial infarction (n¼2 (one esomeprazole 40 mg and
one placebo recipient)), cerebrovascular accident (esomeprazole
20 mg), cardiac arrest (esomeprazole 20 mg), acute coronary
syndrome (esomeprazole 20 mg), small bowel obstruction
(esomeprazole 40 mg), acute renal failure (esomeprazole 40 mg),
sudden death (esomeprazole 40 mg) and death from an
unknown cause (esomeprazole 20 mg). The patient who died as
a result of acute coronary syndrome began taking clopidogrel at
the time of the cardiovascular event; none of the other patients
who died were taking clopidogrel. Serious adverse events other
than death were reported for 5.3% of esomeprazole 40 mg, 4.9%
of esomeprazole 20 mg and 4.4% of placebo recipients; again,
none of these were considered to be causally related to the study
drug. There were no cardiovascular events in patients receiving
clopidogrel, and no further events in patients who experienced
a cardiovascular event and began taking clopidogrel during the
trial (n¼5). The incidence of adverse events categorised as
cardiac disorders was low, and there were no clinically mean-
ingful differences in the incidence of these events among the
treatment groups (2.5%, 2.4% and 2.1% for esomeprazole 40 mg,
20 mg and placebo, respectively).
DISCUSSION
In the OBERON trial, once-daily esomeprazole 40 mg and 20 mg
signiﬁcantly reduced the incidence of endoscopy-conﬁrmed
peptic ulcer, compared with placebo, during 26 weeks of treat-
ment. Esomeprazole had a similar effect among patients taking
ASA between the ranges of 75e100 mg and 101e325 mg.
Table 1 Patient baseline characteristics (intention-to-treat population)
Characteristics
Esomeprazole
Placebo
(n[805)
40 mg once
daily (n[817)
20 mg once
daily (n[804)
Men 437 (53.5) 429 (53.4) 403 (50.1)
Age
Mean, years (range) 67.7 (21e87) 67.7 (24e89) 67.4 (24e94)
>70 years 299 (36.6) 286 (35.6) 282 (35.0)
Ethnicity
White 669 (81.9) 651 (81.0) 661 (82.1)
Black/African-American 30 (3.7) 31 (3.9) 23 (2.9)
Asian 76 (9.3) 77 (9.6) 82 (10.2)
Other* 42 (5.1) 45 (5.6) 39 (4.8)
Current smoker 77 (9.4) 73 (9.1) 73 (9.1)
Helicobacter pylori status
H pylori negative 606 (74.2) 605 (75.2) 574 (71.3)
H pylori positive 159 (19.5) 149 (18.5) 171 (21.2)
Missing/indeterminate
status
52 (6.4) 50 (6.2) 60 (7.4)
History of gastric ulcer 108 (13.2) 100 (12.4) 89 (11.1)
History of duodenal ulcer 111 (13.6) 121 (15.0) 133 (16.5)
History of erosive (reﬂux)
oesophagitis
56 (6.9) 63 (7.8) 61 (7.6)
Past PCI 112 (13.7) 103 (12.8) 102 (12.7)
Past CABG 85 (10.4) 85 (10.6) 81 (10.1)
Low-dose ASA use
Primary prevention 363 (44.4) 368 (45.8) 386 (48.0)
Secondary prevention 435 (53.2) 421 (52.4) 401 (49.8)
Mean dose, mg (range) 112.1 (75e325) 109.2 (50e325) 107.7 (75e325)
101e325 mg/day 178 (21.8) 171 (21.3) 161 (20.0)
>4 weeks’ duration 713 (87.3) 684 (85.1) 700 (87.0)
Variables are n (%) unless otherwise stated.
*Including native Hawaiian/Paciﬁc Islander, American Indian/Alaska native, Hispanic,
Middle Eastern, Caribbean Island, Black/South African or mixed ethnicity.
ASA, acetylsalicylic acid; CABG, coronary artery bypass grafting; PCI, percutaneous
coronary intervention.
Figure 2 Cumulative percentage of
patients with peptic ulcer(s) by week
26 (intention-to-treat population,
KaplaneMeier curve).
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Clinical trialsEsomeprazole in combination with low-dose ASA was well
tolerated and there were no safety concerns. The data from the
OBERON trial support and extend the ﬁndings of the earlier
ASTERIX trial, which demonstrated the efﬁcacy of esomepra-
zole 20 mg in reducing the incidence of peptic ulcers associated
with continuous use of low-dose ASA.
21
The results of the OBERON trial are potentially clinically
relevant in several ways. Although there is a recognised differ-
ence between endoscopic ulcers and bleeding complications,
endoscopic ulcers have been used as clinical markers of gastro-
intestinal end points, based on the rationale that prevention of
ulcer occurrence would reduce the incidence of ulcer bleeds.
22
Indeed, there is evidence that concomitant PPIs decrease hospi-
talisations due to serious gastrointestinal bleeding in patients
taking ASA or non-steroidal anti-inﬂammatory drugs.
23 More
recently, the Clopidogrel and Optimisation of Gastrointestinal
Events Trial (COGENT) showed that prophylactic PPI treat-
ment signiﬁcantly reduced the rate of upper gastrointestinal
bleeding among patients receiving dual antiplatelet treatment,
without a signiﬁcant increase in the risk of cardiovascular
events.
24
Peptic ulcers with the potential for gastrointestinal bleeding
may inﬂuence underlying cardiovascular diseasedfor example,
peptic ulcers can cause anaemia,
25 an independent risk factor for
mortality and hospitalisation in patients with myocardial
infarction.
26Also, gastrointestinal bleeding is independently
associated with mortality and ischaemic complications in
patients with acute coronary syndrome.
27
The results of the OBERON trial extend the ﬁndings of
ASTERIX, providing data that are relevant to clinical practice.
By reﬁning the inclusion criteria for recruiting patients with
higher gastrointestinal risk than those patients who took part in
ASTERIX, OBERON provides data on low-dose ASA users who
are most likely to beneﬁt from concomitant PPIs. Of note, the
risk factors for gastrointestinal bleeding are also important risk
factors for coronary disease.
1 Patients with multiple erosions at
baseline were included in the study as an increased rate of
gastric/duodenal erosions was previously associated with low-
dose ASA treatment.
28 Patients who were naïve to low-dose ASA
treatment were also included, as epidemiological data indicate
that patients treated with ASA develop peptic ulcers at a higher
rate during the initial treatment phase (within 1 month) than
after the initial phase.
11 However, our documented incidence of
peptic ulcer development is still likely to be conservative; higher
ulcer rates have been found in low-dose ASA users elsewhere.
7
Patients with the highest gastrointestinal risk (baseline peptic
ulcers, reﬂux oesophagitis and a history of peptic ulcer compli-
cations) and cardiovascular risk were excluded from this study
for ethical reasons.
The beneﬁt of concomitant PPI treatment in a subgroup of
low-dose ASA recipients at very high gastrointestinal risk, using
ulcer complications as end points, has previously been demon-
strated.
29 Of particular relevance to patients at increased
cardiovascular risk,concomitantlow-doseASAandesomeprazole
treatment signiﬁcantly lowered the risk of recurrent ulcer
bleeding compared with clopidogrel monotherapy.
30 Given these
data, it is not surprising that the use of PPIs for gastroprotection
among patients with gastrointestinal risk factors who require
low-dose ASA or clopidogrel for cardiovascular risk management
is supported by expert opinion in the joint statement by the
American College of Cardiology Foundation, American College of
Gastroenterology and the American Heart Association.
20 More
than 20% of the ITT population were H pylori positive (as
determined by a [
13C]urea breath test), indicating a high level of
false-negative serology screening tests at the study centres. A
similar rate of false-negative tests was also noted during the
ASTERIX trial. In order to preserve the gastrointestinal risk
proﬁle of the patients, the result of the conﬁrmatory test was not
provided to the investigator during the study unless requested.
Since H pylori testing is not always performed in routine clinical
practice before starting antiplatelet treatment, the data support
the efﬁcacy of the treatment in the target population.
Reduction of ulcer development in low-dose ASA users was
recently demonstrated with use of an H2-receptor antagonist
(H2-RA), famotidine, 20 mg twice daily for 3 months.
31 Many
methodological differences between this and our study make
comparisons difﬁcult; of particular note, over 20% of patients in
the famotidine study did not have ﬁnal endoscopic conﬁrmation
of ulcer status. Furthermore, 42% of placebo recipients who
developed ulcers had H pylori infection, versus no instances of
infection in the active treatment group, raising the possibility
that many of the ulcers prevented were attributable to H pylori
infection and not to low-dose ASA. Further, in a longer-term
(48 weeks) trial, famotidine 40 mg/day was shown to be inferior
to a PPI (pantoprazole) in the prevention of dyspeptic or
bleeding ulcers/erosions in patients with ASA-related peptic
ulcers/erosions.
32 Concerns about the long-term use of H2-RAs
for the reduction of low-dose ASA-related ulcers include tachy-
phylaxis, as well as lack of convincing observational data that
bleeding ulcers can be reduced, leading to recommendations
favouring PPI over H2-RA treatment.
20 While the efﬁcacy of
H2-RA treatment in reduction of gastric bleeding has been
observed, the effect was less than has been shown with PPI
treatment.
33 The efﬁcacy of esomeprazole 40 mg and 20 mg was
shown in an OBERON analysis for both the H pylori-negative
population and patients proved to be H pylori positive after
randomisation. The same observation was made in the
ASTERIX study, which used esomeprazole 20 mg daily.
21
Table 2 Number (%) of patients with adverse events (safety
population)
Patients with adverse events
Esomeprazole
Placebo
(n[801)
40 mg once
daily (n[814)
20 mg once
daily (n[799)
Any adverse events, n (%) 295 (36.2) 297 (37.2) 298 (37.2)
Fatal serious adverse events, n (%)* 4 (0.5) 4 (0.5) 1 (0.1)
Non-fatal serious adverse
events, n (%)*
43 (5.3) 39 (4.9) 35 (4.4)
Adverse events leading to
treatment withdrawal, n(%)
30 (3.7) 37 (4.6) 42 (5.2)
Treatment-related adverse
events, n (%)
34 (4.2) 39 (4.9) 31 (3.9)
Most common adverse events, n (%)
Diarrhoea 21 (2.6) 27 (3.4) 18 (2.2)
Headache 15 (1.8) 15 (1.9) 15 (1.9)
Bronchitis 11 (1.4) 17 (2.1) 14 (1.7)
Upper abdominal pain 13 (1.6) 7 (0.9) 15 (1.9)
Inﬂuenza 11 (1.4) 9 (1.1) 13 (1.6)
Back pain 8 (1.0) 9 (1.1) 14 (1.7)
Nasopharyngitis 7 (0.9) 13 (1.6) 10 (1.2)
Upper respiratory tract infection 7 (0.9) 8 (1.0) 15 (1.9)
Dizziness 7 (0.9) 9 (1.1) 12 (1.5)
Nausea 15 (1.8) 6 (0.8) 6 (0.7)
Constipation 9 (1.1) 10 (1.3) 6 (0.7)
Hypertension 10 (1.2) 8 (1.0) 7 (0.9)
Urinary tract infection 6 (0.7) 10 (1.3) 8 (1.0)
Dyspepsia 7 (0.9) 3 (0.4) 12 (1.5)
*No serious adverse event was considered by the investigators to be causally related to the
study drug.
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Clinical trialsIn conclusion, the results of this trial demonstrate that
esomeprazole 40 mg and 20 mg once daily reduces the risk of
endoscopically proved peptic ulcer in patients who take
low-dose ASA, and who are at risk for ulcer development. In
the population studied, the esomeprazole 40 mg and 20 mg
regimens appear to be equally effective.
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